Increased  ||| S:0 E:10 ||| JJ
prevalence  ||| S:10 E:21 ||| NN
of  ||| S:21 E:24 ||| IN
early  ||| S:24 E:30 ||| JJ
repolarization  ||| S:30 E:45 ||| NN
in  ||| S:45 E:48 ||| IN
electrocardiograms  ||| S:48 E:67 ||| NN
of  ||| S:67 E:70 ||| IN
psoriatic  ||| S:70 E:80 ||| JJ
patients  ||| S:80 E:89 ||| NNS
Psoriasis  ||| S:89 E:99 ||| NNP
( ||| S:99 E:100 ||| -LRB-
Ps ||| S:100 E:102 ||| NNP
)  ||| S:102 E:104 ||| -RRB-
is  ||| S:104 E:107 ||| VBZ
a  ||| S:107 E:109 ||| DT
chronic-relapsing ||| S:109 E:126 ||| JJ
,  ||| S:126 E:128 ||| ,
inflammatory ||| S:128 E:140 ||| JJ
,  ||| S:140 E:142 ||| ,
and  ||| S:142 E:146 ||| CC
proliferative  ||| S:146 E:160 ||| JJ
condition  ||| S:160 E:170 ||| NN
of  ||| S:170 E:173 ||| IN
the  ||| S:173 E:177 ||| DT
skin ||| S:177 E:181 ||| NN
:  ||| S:181 E:183 ||| :
prior  ||| S:183 E:189 ||| JJ
studies  ||| S:189 E:197 ||| NNS
hypothesized  ||| S:197 E:210 ||| VBP
a  ||| S:210 E:212 ||| DT
link  ||| S:212 E:217 ||| NN
between  ||| S:217 E:225 ||| IN
Ps  ||| S:225 E:228 ||| NNP
and  ||| S:228 E:232 ||| CC
anomalies  ||| S:232 E:242 ||| NN
in  ||| S:242 E:245 ||| IN
β-adrenergic  ||| S:245 E:258 ||| JJ
tone ||| S:258 E:262 ||| NN
.  ||| S:262 E:264 ||| .
We  ||| S:264 E:267 ||| PRP
therefore  ||| S:267 E:277 ||| RB
aimed  ||| S:277 E:283 ||| VBN
to  ||| S:283 E:286 ||| TO
ascertain  ||| S:286 E:296 ||| VB
the  ||| S:296 E:300 ||| DT
prevalence  ||| S:300 E:311 ||| NN
of  ||| S:311 E:314 ||| IN
early  ||| S:314 E:320 ||| JJ
repolarization  ||| S:320 E:335 ||| JJ
pattern  ||| S:335 E:343 ||| NN
( ||| S:343 E:344 ||| -LRB-
ERP ||| S:344 E:347 ||| NNP
)  ||| S:347 E:349 ||| -RRB-
in  ||| S:349 E:352 ||| IN
resting  ||| S:352 E:360 ||| JJ
electrocardiograms  ||| S:360 E:379 ||| NNS
( ||| S:379 E:380 ||| -LRB-
ECGs ||| S:380 E:384 ||| NNP
)  ||| S:384 E:386 ||| -RRB-
of  ||| S:386 E:389 ||| IN
psoriatic  ||| S:389 E:399 ||| JJ
patients  ||| S:399 E:408 ||| NNS
compared  ||| S:408 E:417 ||| VBN
with  ||| S:417 E:422 ||| IN
an  ||| S:422 E:425 ||| DT
appropriate  ||| S:425 E:437 ||| JJ
control  ||| S:437 E:445 ||| NN
group ||| S:445 E:450 ||| NN
.  ||| S:450 E:452 ||| .
We  ||| S:452 E:455 ||| PRP
performed  ||| S:455 E:465 ||| VBD
a  ||| S:465 E:467 ||| DT
retrospective  ||| S:467 E:481 ||| JJ
study  ||| S:481 E:487 ||| NN
of  ||| S:487 E:490 ||| IN
resting  ||| S:490 E:498 ||| JJ
ECGs  ||| S:498 E:503 ||| NN
of  ||| S:503 E:506 ||| IN
100  ||| S:506 E:510 ||| CD
consecutive  ||| S:510 E:522 ||| JJ
psoriatic  ||| S:522 E:532 ||| JJ
patients  ||| S:532 E:541 ||| NNS
and  ||| S:541 E:545 ||| CC
100  ||| S:545 E:549 ||| CD
healthy  ||| S:549 E:557 ||| JJ
controls ||| S:557 E:565 ||| NNS
.  ||| S:565 E:567 ||| .
The  ||| S:567 E:571 ||| DT
presence  ||| S:571 E:580 ||| NN
of  ||| S:580 E:583 ||| IN
ERP  ||| S:583 E:587 ||| NNP
in  ||| S:587 E:590 ||| IN
at  ||| S:590 E:593 ||| IN
least  ||| S:593 E:599 ||| JJS
two  ||| S:599 E:603 ||| CD
contiguous  ||| S:603 E:614 ||| JJ
leads  ||| S:614 E:620 ||| NNS
at  ||| S:620 E:623 ||| IN
rest  ||| S:623 E:628 ||| NN
ECG  ||| S:628 E:632 ||| NNP
was  ||| S:632 E:636 ||| VBD
recorded ||| S:636 E:644 ||| VBN
,  ||| S:644 E:646 ||| ,
and  ||| S:646 E:650 ||| CC
findings  ||| S:650 E:659 ||| NNS
were  ||| S:659 E:664 ||| VBD
also  ||| S:664 E:669 ||| RB
categorized  ||| S:669 E:681 ||| VBN
according  ||| S:681 E:691 ||| VBG
to  ||| S:691 E:694 ||| TO
the  ||| S:694 E:698 ||| DT
lead  ||| S:698 E:703 ||| JJ
group  ||| S:703 E:709 ||| NN
where  ||| S:709 E:715 ||| WRB
ERP  ||| S:715 E:719 ||| NNP
was  ||| S:719 E:723 ||| VBD
detected  ||| S:723 E:732 ||| VBN
( ||| S:732 E:733 ||| -LRB-
anterior ||| S:733 E:741 ||| UH
,  ||| S:741 E:743 ||| ,
lateral ||| S:743 E:750 ||| NN
,  ||| S:750 E:752 ||| ,
inferior ||| S:752 E:760 ||| JJ
) ||| S:760 E:761 ||| -RRB-
.  ||| S:761 E:763 ||| .
An  ||| S:763 E:766 ||| DT
ERP  ||| S:766 E:770 ||| NNP
in  ||| S:770 E:773 ||| IN
≥2  ||| S:773 E:776 ||| CD
contiguous  ||| S:776 E:787 ||| NN
leads  ||| S:787 E:793 ||| VBZ
occurred  ||| S:793 E:802 ||| VBN
in  ||| S:802 E:805 ||| IN
40  ||| S:805 E:808 ||| CD
%  ||| S:808 E:810 ||| NN
of  ||| S:810 E:813 ||| IN
psoriatic  ||| S:813 E:823 ||| JJ
patients ||| S:823 E:831 ||| NNS
,  ||| S:831 E:833 ||| ,
compared  ||| S:833 E:842 ||| VBN
with  ||| S:842 E:847 ||| IN
14  ||| S:847 E:850 ||| CD
%  ||| S:850 E:852 ||| NN
of  ||| S:852 E:855 ||| IN
control  ||| S:855 E:863 ||| NN
subjects  ||| S:863 E:872 ||| NNS
( ||| S:872 E:873 ||| -LRB-
p   ||| S:873 E:875 ||| NNP
< ||| S:875 E:876 ||| SYM
 0.001 ||| S:876 E:882 ||| NNP
) ||| S:882 E:883 ||| -RRB-
.  ||| S:883 E:885 ||| .
( ||| S:885 E:886 ||| -LRB-
36  ||| S:886 E:889 ||| CD
vs  ||| S:889 E:892 ||| CD
10  ||| S:892 E:895 ||| CD
%  ||| S:895 E:897 ||| NN
in  ||| S:897 E:900 ||| IN
anterior  ||| S:900 E:909 ||| JJ
leads ||| S:909 E:914 ||| NNS
,  ||| S:914 E:916 ||| ,
p   ||| S:916 E:918 ||| NNP
< ||| S:918 E:919 ||| SYM
 0.001 ||| S:919 E:925 ||| NNP
;  ||| S:925 E:927 ||| :
6  ||| S:927 E:929 ||| CD
vs  ||| S:929 E:932 ||| CD
3  ||| S:932 E:934 ||| CD
%  ||| S:934 E:936 ||| NN
in  ||| S:936 E:939 ||| IN
inferior  ||| S:939 E:948 ||| JJ
leads ||| S:948 E:953 ||| NNS
,  ||| S:953 E:955 ||| ,
p  ||| S:955 E:957 ||| CD
n.s. ||| S:957 E:961 ||| CD
;  ||| S:961 E:963 ||| :
10  ||| S:963 E:966 ||| CD
vs  ||| S:966 E:969 ||| CD
2  ||| S:969 E:971 ||| CD
%  ||| S:971 E:973 ||| NN
in  ||| S:973 E:976 ||| IN
lateral  ||| S:976 E:984 ||| JJ
leads ||| S:984 E:989 ||| NNS
) ||| S:989 E:990 ||| -RRB-
.  ||| S:990 E:992 ||| .
After  ||| S:992 E:998 ||| IN
adjustment  ||| S:998 E:1009 ||| NN
for  ||| S:1009 E:1013 ||| IN
sex ||| S:1013 E:1016 ||| NN
,  ||| S:1016 E:1018 ||| ,
age ||| S:1018 E:1021 ||| NN
,  ||| S:1021 E:1023 ||| ,
heart  ||| S:1023 E:1029 ||| NN
rate ||| S:1029 E:1033 ||| NN
,  ||| S:1033 E:1035 ||| ,
and  ||| S:1035 E:1039 ||| CC
level  ||| S:1039 E:1045 ||| NN
of  ||| S:1045 E:1048 ||| IN
physical  ||| S:1048 E:1057 ||| JJ
activity ||| S:1057 E:1065 ||| NN
,  ||| S:1065 E:1067 ||| ,
the  ||| S:1067 E:1071 ||| DT
odds  ||| S:1071 E:1076 ||| JJ
ratios  ||| S:1076 E:1083 ||| NNS
for  ||| S:1083 E:1087 ||| IN
the  ||| S:1087 E:1091 ||| DT
presence  ||| S:1091 E:1100 ||| NN
of  ||| S:1100 E:1103 ||| IN
ERP  ||| S:1103 E:1107 ||| NNP
were  ||| S:1107 E:1112 ||| VBD
8.6  ||| S:1112 E:1116 ||| CD
( ||| S:1116 E:1117 ||| -LRB-
95  ||| S:1117 E:1120 ||| NNP
%  ||| S:1120 E:1122 ||| NN
CI ||| S:1122 E:1124 ||| NNP
,  ||| S:1124 E:1126 ||| ,
2.1-35.2 ||| S:1126 E:1134 ||| NNP
,  ||| S:1134 E:1136 ||| ,
p   ||| S:1136 E:1138 ||| CD
< ||| S:1138 E:1139 ||| SYM
 0.01 ||| S:1139 E:1144 ||| CD
) ||| S:1144 E:1145 ||| -RRB-
,  ||| S:1145 E:1147 ||| ,
and  ||| S:1147 E:1151 ||| CC
7.1  ||| S:1151 E:1155 ||| CD
( ||| S:1155 E:1156 ||| -LRB-
95  ||| S:1156 E:1159 ||| NNP
%  ||| S:1159 E:1161 ||| NN
CI ||| S:1161 E:1163 ||| NNP
,  ||| S:1163 E:1165 ||| ,
1.6-31.8 ||| S:1165 E:1173 ||| NNP
,  ||| S:1173 E:1175 ||| ,
p   ||| S:1175 E:1177 ||| CD
< ||| S:1177 E:1178 ||| SYM
 0.05 ||| S:1178 E:1183 ||| CD
)  ||| S:1183 E:1185 ||| -RRB-
in  ||| S:1185 E:1188 ||| IN
anterior  ||| S:1188 E:1197 ||| JJ
leads ||| S:1197 E:1202 ||| NNS
.  ||| S:1202 E:1204 ||| .
In  ||| S:1204 E:1207 ||| IN
a  ||| S:1207 E:1209 ||| DT
small  ||| S:1209 E:1215 ||| JJ
case ||| S:1215 E:1219 ||| NN
/ ||| S:1219 E:1220 ||| CD
control  ||| S:1220 E:1228 ||| NN
study ||| S:1228 E:1233 ||| NN
,  ||| S:1233 E:1235 ||| ,
increased  ||| S:1235 E:1245 ||| VBD
rates  ||| S:1245 E:1251 ||| NNS
of  ||| S:1251 E:1254 ||| IN
ECGs  ||| S:1254 E:1259 ||| JJ
showing  ||| S:1259 E:1267 ||| NN
ERP  ||| S:1267 E:1271 ||| NNS
have  ||| S:1271 E:1276 ||| VBP
been  ||| S:1276 E:1281 ||| VBN
observed  ||| S:1281 E:1290 ||| VBN
among  ||| S:1290 E:1296 ||| IN
psoriatic  ||| S:1296 E:1306 ||| JJ
patients ||| S:1306 E:1314 ||| NNS
.  ||| S:1314 E:1316 ||| .
Clinical  ||| S:1316 E:1325 ||| JJ
significance  ||| S:1325 E:1338 ||| NN
of  ||| S:1338 E:1341 ||| IN
such  ||| S:1341 E:1346 ||| JJ
finding  ||| S:1346 E:1354 ||| NN
needs  ||| S:1354 E:1360 ||| VBZ
to  ||| S:1360 E:1363 ||| TO
be  ||| S:1363 E:1366 ||| VB
assessed  ||| S:1366 E:1375 ||| VBN
in  ||| S:1375 E:1378 ||| IN
further  ||| S:1378 E:1386 ||| JJ
observational  ||| S:1386 E:1400 ||| JJ
studies ||| S:1400 E:1407 ||| NNS
.  ||| S:1407 E:1409 ||| .
